DBV Technologies (DBVT) Cash from Operations (2020 - 2026)
DBV Technologies (DBVT) posted Cash from Operations of 52600000.0 for Q2 2026, down 7.13% sequentially from 49100000.0 in Q1 2026, and down 55.16% YoY from 117311842.11 in Q2 2025.
DBV Technologies (DBVT) Cash from Operations (2020 - 2026) Analysis & Trends
DBV Technologies has reported Cash from Operations for 7 years, with the latest figure at 52600000.0 in Q2 2026.
- Quarterly Cash from Operations fell 55.16% year-over-year to 52600000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 169281000.0 (down 91.69% YoY) and the FY2025 annual result came in at 121181000.0, down 15.99% from the prior year.
- Cash from Operations slipped to 52600000.0 in Q2 2026 per DBVT's latest filing, from 49100000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 1483000.0 in Q1 2022 and troughed at 52600000.0 in Q2 2026.
- A 5-year average of 25704111.11 and a median of 23171000.0 in 2022 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2022 and 2023: Cash from Operations jumped 95.9% in 2022, then slumped 1305.33% in 2023.
- Over 5 years, Cash from Operations stood at 23885000.0 in 2022, then surged by 42.7% to 13686000.0 in 2023, then grew by 10.48% to 12252000.0 in 2024, then slumped by 187.08% to 35173000.0 in 2025, then plunged by 49.55% to 52600000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 52600000.0, 49100000.0, and 35173000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | DBV Technologies | 6.08 Bn | 5.90 Bn | - | -52.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -52.60 Mn |
| Jun 30, 2026 | -52.60 Mn |
| Mar 31, 2026 | -49.10 Mn |
| Mar 31, 2026 | -49.10 Mn |
| Dec 31, 2025 | -35.17 Mn |
| Dec 31, 2025 | -35.17 Mn |
| Sep 30, 2025 | -32.41 Mn |
| Sep 30, 2025 | -32.41 Mn |
| Jun 30, 2025 | -33.90 Mn |
| Jun 30, 2025 | -33.90 Mn |
| Mar 31, 2025 | -19.70 Mn |
| Mar 31, 2025 | -19.70 Mn |
| Dec 31, 2024 | -12.25 Mn |
| Dec 31, 2024 | -12.25 Mn |
| Sep 30, 2024 | -22.46 Mn |
| Sep 30, 2024 | -22.46 Mn |
| Jun 30, 2024 | -35.07 Mn |
| Jun 30, 2024 | -35.07 Mn |
| Mar 31, 2024 | -34.69 Mn |
| Mar 31, 2024 | -34.69 Mn |